These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 31814586)

  • 21. Association of a reduction in low-density lipoprotein cholesterol with incident cardiovascular and cerebrovascular events among people with type 2 diabetes mellitus.
    Li L; Ambegaonkar BM; Reckless JP; Jick S
    Eur J Prev Cardiol; 2014 Jul; 21(7):855-65. PubMed ID: 23460659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes.
    Yun JS; Ko SH
    Metabolism; 2021 Oct; 123():154838. PubMed ID: 34333002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The influence of metformin and the presence of type 2 diabetes mellitus on mortality and hospitalisation in patients with heart failure.
    Retwiński A; Kosmalski M; Crespo-Leiro M; Maggioni A; Opolski G; Ponikowski P; Poloński L; Jankowska E; Drzewoski J; Drożdż J
    Kardiol Pol; 2018; 76(9):1336-1343. PubMed ID: 29862487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort.
    Wahlqvist ML; Lee MS; Hsu CC; Chuang SY; Lee JT; Tsai HN
    Parkinsonism Relat Disord; 2012 Jul; 18(6):753-8. PubMed ID: 22498320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucose, cholesterol and blood pressure in type II diabetes: A longitudinal observational study comparing patients with and without severe mental illness.
    Smith R; Han L; Ali S; Prady SL; Taylor J; Hughes T; Ajjan RA; Siddiqi N; Doran T
    J Psychiatr Ment Health Nurs; 2019 Nov; 26(9-10):347-357. PubMed ID: 31287193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study.
    Chang YC; Chuang LM; Lin JW; Chen ST; Lai MS; Chang CH
    Diabet Med; 2015 Nov; 32(11):1460-9. PubMed ID: 25970814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care.
    Hippisley-Cox J; Coupland C
    BMJ; 2016 Jul; 354():i3477. PubMed ID: 27413012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral hypoglycaemic agents and the development of non-fatal cardiovascular events in patients with type 2 diabetes mellitus.
    Hung YC; Lin CC; Wang TY; Chang MP; Sung FC; Chen CC
    Diabetes Metab Res Rev; 2013 Nov; 29(8):673-9. PubMed ID: 23956007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
    Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
    Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. All-cause mortality and cardiovascular events in a Spanish nonagenarian cohort according to type 2 diabetes mellitus status and established cardiovascular disease.
    Salinero-Fort MA; Mostaza J; Lahoz C; Cárdenas-Valladolid J; Vicente-Díez JI; Gómez-Campelo P; de Miguel-Yanes JM
    BMC Geriatr; 2022 Mar; 22(1):224. PubMed ID: 35303825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings.
    Shehab A; Al-Rasadi K; Arafah M; Al-Hinai AT; Al Mahmeed W; Bhagavathula AS; Al Tamimi O; Al Herz S; Al Anazi F; Al Nemer K; Metwally O; Alkhadra A; Fakhry M; Elghetany H; Medani AR; Yusufali AH; Al Jassim O; Al Hallaq O; Baslaib FOAS; Alawadhi M; Amin H; Al-Hashmi K; Oulhaj A
    Curr Vasc Pharmacol; 2018; 16(4):368-375. PubMed ID: 28677510
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study.
    Douros A; Dell'Aniello S; Yu OHY; Filion KB; Azoulay L; Suissa S
    BMJ; 2018 Jul; 362():k2693. PubMed ID: 30021781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Control of Cardiovascular Risk Factors Among US Adults With Type 2 Diabetes With and Without Cardiovascular Disease.
    Andary R; Fan W; Wong ND
    Am J Cardiol; 2019 Aug; 124(4):522-527. PubMed ID: 31239072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Large impact of antidiabetic drug treatment and hospitalizations on economic burden of diabetes mellitus in The Netherlands during 2000 to 2004.
    van der Linden MW; Plat AW; Erkens JA; Emneus M; Herings RM
    Value Health; 2009 Sep; 12(6):909-14. PubMed ID: 19508664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
    Dailey G
    Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
    Paneni F; Lüscher TF
    Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world evidence of suboptimal blood pressure control in patients with type 2 diabetes.
    Walraven I; Mast MR; Hoekstra T; Jansen AP; Rauh SP; Rutters FR; van der Heijden AA; Elders PJ; Moll AC; Polak BC; Dekker JM; Nijpels G
    J Hypertens; 2015 Oct; 33(10):2091-8. PubMed ID: 26237560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
    Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
    Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cardiovascular Effects of Antidiabetic Therapies].
    Laubner K; Seufert J
    Dtsch Med Wochenschr; 2017 May; 142(10):737-745. PubMed ID: 28514822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.